Genentech/Idec Rituxan Letter Warns Of Fatal Mucocutaneous Reactions
Executive Summary
Fatal mucocutaneous reactions to Genentech/Idec's Rituxan non-Hodgkin's lymphoma treatment are the subject of a "Dear Healthcare Provider" letter sent to oncologists May 8.
You may also be interested in...
Genentech, FDA Discussing Herceptin Label Changes To Reflect New PK Data
Genentech and FDA are discussing updates to Herceptin labeling following the submission of preliminary data suggesting the half-life of trastuzumab is up to five times longer than previously thought.
Genentech, FDA Discussing Herceptin Label Changes To Reflect New PK Data
Genentech and FDA are discussing updates to Herceptin labeling following the submission of preliminary data suggesting the half-life of trastuzumab is up to five times longer than previously thought.
Genentech Rituxan Promo Effort To Expand With Broader Lymphoma Label
Genentech will be able to increase promotional activity for its non-Hodgkin's lymphoma treatment Rituxan (rituximab) in the next two months as more indications for the drug come on-label, Chief Operating Officer Myrtle Potter told an analyst meeting in New York City Feb. 21.